← Leaderboards
Heather Cody Hazlett
Brigham And Women'S Hospital
$6,380,714
Attributed
$9,638,794
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2008–24$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$9,638,794 · 5
By mechanism
R01$5,991,987 · 2
U01$2,927,457 · 1
R56$544,250 · 1
U54$175,100 · 1
Top collaborators
- Benjamin D Philpot6 shared
- Natasha Marrus1 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Matthew P Anderson$9,694,050
- Stephan E Maier$7,745,020
Others in their field
Top investigators on “Magnetic Resonance Imaging”
- Michael W Weiner · Northern California Institute Res &Educ$151,227,246
- Paul S. Aisen · Cognition Therapeutics, Inc.$114,102,468
- Reisa A. Sperling · Banner Health$112,709,449
- Randall J Bateman · Washington University$108,056,165
- Peter Gordon Gillespie · Oregon Health And Science University$104,808,120
- Joseph E Robertson · Oregon Health & Science University$93,739,249
Research focus
Magnetic Resonance ImagingDiffusion Magnetic Resonance ImagingPathway InteractionsNeuroimagingSeveritiesWhite MatterChildBehavioralGrowthBehaviorSiteBrainSamplingPhenotypePostnatalStructureMyelinationImaging StudyIntellectual Functioning DisabilityExhibitsEvaluationMotor SkillsPatternFiber
Grant awards (13)
The Infant Down Syndrome Brain and Behavior Study$2,927,457
U01 · FY2024 · HD
White Matter Pathology in Angelman Syndrome and Its Potential as an Outcome Measure in Clinical Trials$587,533
R01 · FY2022 · HD
White Matter Pathology in Angelman Syndrome and Its Potential as an Outcome Measure in Clinical Trials$595,604
R01 · FY2021 · HD
White Matter Pathology in Angelman Syndrome and Its Potential as an Outcome Measure in Clinical Trials$612,696
R01 · FY2020 · HD
White Matter Pathology in Angelman Syndrome and Its Potential as an Outcome Measure in Clinical Trials$621,084
R01 · FY2019 · HD
White Matter Pathology in Angelman Syndrome and Its Potential as an Outcome Measure in Clinical Trials$627,537
R01 · FY2018 · HD
White Matter Fiber Tract Pathology in a Genetically-Defined Neurodevelopmental Disorder$544,250
R56 · FY2017 · NS
A Longitudinal MRI Study of Brain Development in Fragile X Syndrome$548,356
R01 · FY2014 · HD · contact PI
A Longitudinal MRI Study of Brain Development in Fragile X Syndrome$549,582
R01 · FY2013 · HD · contact PI
A Longitudinal MRI Study of Brain Development in Fragile X Syndrome$610,416
R01 · FY2012 · HD · contact PI
A Longitudinal MRI Study of Brain Development in Fragile X Syndrome$617,080
R01 · FY2010 · HD · contact PI
A Longitudinal MRI Study of Brain Development in Fragile X Syndrome$622,099
R01 · FY2009 · HD · contact PI
STRUCTURAL AND FUNCTIONAL CONNECTIVITY IN SCHIZOPHRENIA IN NEUROPSYCHIATRIC DISOR$175,100
U54 · FY2008 · EB · contact PI